Albany Molecular Research

Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Solutions (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Drug Product Manufacturing supports development through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal) and Facebook (@AlbanyMolecularResearchInc).
Type
Public
HQ
Albany, US
Founded
1991
Size (employees)
2,220 (est)
Albany Molecular Research was founded in 1991 and is headquartered in Albany, US

Albany Molecular Research Office Locations

Albany Molecular Research has an office in Albany
Albany, US (HQ)
26 Corporate Cir

Albany Molecular Research Metrics

Albany Molecular Research Financial Metrics

Revenue (2016)

$570.5 m

Revenue growth (2015-16), %

42%

Net income (2016)

($70.2 m)

Market capitalization (21-Mar-2017)

$571.9 m

Closing share price (21-Mar-2017)

$13.9

Cash (31-Dec-2016)

$52 m
Albany Molecular Research's current market capitalization is $571.9 m.
Albany Molecular Research's revenue was reported to be $570.5 m in 2016
FY, 2013FY, 2014FY, 2015Y, 2016

Revenue

$246.6 m$276.6 m$402.4 m$570.5 m

Revenue growth, %

12%45%42%

Operating expense total

$226.4 m$270.8 m$388.7 m$589.2 m

EBIT

$20.2 m$5.7 m$13.6 m($18.8 m)

EBIT margin, %

8%2%3%(3%)

Interest expense

($1.3 m)($11 m)($19.4 m)($39.9 m)

Interest income

$11 k$3 k$14 k($39.9 m)

Income tax expense

$7 m($2.2 m)($1.2 m)$10.2 m

Net Income

$12.7 m($3.3 m)($2.3 m)($70.2 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$175.9 m$47 m$49.3 m$52 m

Accounts Receivable

$52.2 m$71.6 m$110.4 m$144.8 m

Inventories

$7.1 m$11 m$16.2 m$22.1 m

Current Assets

$279 m$191 m$280.2 m$392.9 m

PP&E

$127.8 m$165.5 m$209.5 m$364.8 m

Goodwill

$61.8 m$169.5 m$231.3 m

Total Assets

$445.3 m$520 m$865.6 m$1.2 b

Accounts Payable

$24.2 m$32.2 m$60.9 m$111.1 m

Current Liabilities

$43.9 m$48.7 m$99.1 m$175.5 m

Additional Paid-in Capital

$235.8 m$243.9 m$296.3 m$400.5 m

Retained Earnings

$87.9 m$79.6 m$77.3 m$7.2 m

Total Equity

$241.8 m$287.2 m$299 m

Financial Leverage

2.2 x3 x4 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$12.7 m($3.3 m)($2.3 m)($70.2 m)

Depreciation and Amortization

$15.9 m$18.4 m$27 m$50.6 m

Accounts Receivable

($10 m)($13 m)($9.4 m)($11 m)

Inventories

($5.1 m)($8 m)$7.7 m$21.5 m

Accounts Payable

Cash From Operating Activities

$28.2 m$1.9 m$39.6 m$26.6 m

Purchases of PP&E

($11.1 m)($17.2 m)($22 m)($51.4 m)

Cash From Investing Activities

($11.2 m)($163.3 m)($221.7 m)($193.2 m)

Long-term Borrowings

($775 k)($5.1 m)($81.9 m)($49 m)

Cash From Financing Activities

$136.9 m$33.2 m$185.4 m$170.8 m

Interest Paid

$1.3 m$3.5 m$11.6 m$21.4 m

Income Taxes Paid

$3.4 m$5.9 m$8.2 m$8.3 m

Albany Molecular Research Market Value History

Albany Molecular Research Median Salaries

Source: 43 public H-1B filings from Albany Molecular Research

Albany Molecular Research Online Presence

Albany Molecular Research Company Life

You may also be interested in